Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference

January 05, 2022 at 08:30 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company’s president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10 – 13, 2022. A pre-recorded presentation will be available beginning Monday, January 10 at 7:00 a.m. Eastern time. Interested parties may access a webcast of the presentation on the investor relations section of the Company’s website and at this link.

About Bone Biologics

Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking groundbreaking work with select strategic partners, building on unprecedented research on the Nell-1 protein that has produced a significant number of studies and publications in peer reviewed scientific literature. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion and has rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.